Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from Brokerages

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has earned a consensus rating of "Buy" from the six analysts that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year is $12.20.

Separately, HC Wainwright reissued a "buy" rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Monday, April 14th.

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TNGX. Dynamic Technology Lab Private Ltd bought a new position in shares of Tango Therapeutics in the fourth quarter worth approximately $33,000. Stonebrook Private Inc. bought a new position in Tango Therapeutics in the 4th quarter worth $34,000. Ameriprise Financial Inc. purchased a new stake in Tango Therapeutics in the 4th quarter worth $35,000. Sherbrooke Park Advisers LLC bought a new stake in Tango Therapeutics during the fourth quarter valued at about $38,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Tango Therapeutics in the fourth quarter valued at about $40,000. Institutional investors own 78.99% of the company's stock.

Tango Therapeutics Price Performance

Shares of TNGX traded up $0.32 during trading hours on Friday, hitting $5.44. The stock had a trading volume of 2,226,123 shares, compared to its average volume of 1,575,211. The firm has a market capitalization of $589.64 million, a PE ratio of -4.46 and a beta of 1.61. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $12.02. The stock has a fifty day moving average price of $2.91 and a 200 day moving average price of $2.53.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 62.75% and a negative net margin of 322.67%. The firm had revenue of $5.39 million during the quarter, compared to analysts' expectations of $6.73 million. As a group, analysts anticipate that Tango Therapeutics will post -1.19 EPS for the current fiscal year.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.